Related Experiment Video
Updated: Jul 18, 2025

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
Precision therapy for a medically actionable ATP1A3 variant from a genomic medicine program in an underserved
Cara P Ford1,2, Rebecca O Littlejohn3,4, Ryan German4,5
1School of Medicine, Meharry Medical College, Nashville, Tennessee, USA.
Genomic medicine diagnosed a rare genetic disorder in an underrepresented child denied exome sequencing. Whole exome sequencing identified a pathogenic ATP1A3 variant, enabling targeted treatment and improving outcomes.
Area of Science:
- Genomic Medicine
- Rare Disease Diagnosis
- Clinical Genetics
Background:
- Genomic medicine advances rare disease diagnosis but disparities exist in underrepresented populations.
- A 7-year-old boy with hypotonia, developmental delay, and seizures, from an underrepresented minority, faced insurance barriers to exome sequencing.
- Previous suspicion of mitochondrial myopathy was inconclusive.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...